Jazz Pharmaceuticals Plc PT Raised to $98.00 at UBS AG (JAZZ)
UBS AG lifted their target price on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) to $98.00 in a research note issued on Friday, Analyst Ratings Network.com reports. UBS AG’s target price points to a potential upside of 12.22% from the company’s current price.
A number of other firms have also recently commented on JAZZ. Analysts at R. F. Lafferty initiated coverage on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) in a research note to investors on Thursday, August 22nd. They set a “buy” rating and a $102.00 price target on the stock. Separately, analysts at Lazard Capital Markets raised their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $87.00 to $93.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $66.00 to $74.00 in a research note to investors on Wednesday, August 7th.
Eleven research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $85.14.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 0.35% on Friday, hitting $87.02. The stock had a trading volume of 156,808 shares. Jazz Pharmaceuticals Plc has a 1-year low of $47.37 and a 1-year high of $89.00. The stock has a 50-day moving average of $82.07 and a 200-day moving average of $67.11. The company has a market cap of $5.060 billion and a price-to-earnings ratio of 16.75.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 6th. The company reported $1.43 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.52 by $0.09. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $208.71 million. During the same quarter last year, the company posted $1.09 earnings per share. Jazz Pharmaceuticals Plc’s revenue was up 67.7% compared to the same quarter last year. Analysts expect that Jazz Pharmaceuticals Plc will post $6.30 EPS for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.